

1 **Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP,**  
2 **and a rapid antigen test to diagnose COVID-19**

3

4 Mayu Ikeda<sup>a†</sup>, Kazuo Imai<sup>ab†\*</sup>, Sakiko Tabata<sup>a</sup>, Kazuyasu Miyoshi<sup>a</sup>, Nami Murahara<sup>a</sup>, Tsukasa  
5 Mizuno<sup>a</sup>, Midori Horiuchi<sup>a</sup>, Kento Kato<sup>a</sup>, Yoshitaka Imoto<sup>a</sup>, Maki Iwata<sup>a</sup>, Satoshi Mimura<sup>a</sup>,  
6 Toshimitsu Ito<sup>a</sup>, Kaku Tamura<sup>a</sup>, Yasuyuki Kato<sup>c</sup>

7 †Both authors contributed equally to this manuscript.

8

9 <sup>a</sup>Self-Defense Forces Central Hospital, Tokyo, Japan

10 <sup>b</sup>Department of Infectious Disease and Infection Control, Saitama Medical University,  
11 Saitama, Japan

12 <sup>c</sup>Department of Infectious Diseases, International University of Health and Welfare Narita  
13 Hospital, Chiba, Japan

14

15 **\*Corresponding author:**

16 Kazuo Imai, M.D.

17 Self-Defense Forces Central Hospital, 24-2-1 Ikejiri, Setagaya-ku, Tokyo, 154-0001, Japan

18 E-mail: [k\\_imai@saitama-med.ac.jp](mailto:k_imai@saitama-med.ac.jp)

19 Tel: +81-3-3411-0151

20

21 **Alternate corresponding author:**

22 Kazuyasu Miyoshi, M.D.

23 Self-Defense Forces Central Hospital, 24-2-1 Ikejiri, Setagaya-ku, Tokyo, 154-0001, Japan

24 E-mail: [kazuyasu344@gmail.com](mailto:kazuyasu344@gmail.com)

25 Tel: +81-3-3411-0151

26 **Key words;** SARS-CoV-2, Saliva, RT-qPCR, RT-LAMP, antigen test

27

28 **Running title:** Diagnosing COVID-19 using saliva

29

30 **Key points:** Six molecular diagnostic tests showed equivalent and sufficient sensitivity in

31 clinical use in diagnosing COVID-19 in self-collected saliva samples. However, a rapid

32 SARS-CoV-2 antigen test alone is not recommended for use without further study.

33

34 **Abstract**

35 **Background:** The clinical performance of six molecular diagnostic tests and a rapid antigen

36 test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were clinically

37 evaluated for the diagnosis of coronavirus disease 2019 (COVID-19) in self-collected saliva.

38 **Methods:** Saliva samples from 103 patients with laboratory-confirmed COVID-19 (15

39 asymptomatic and 88 symptomatic) were collected on the day of hospital admission.

40 SARS-CoV-2 RNA in saliva was detected using a quantitative reverse-transcription

41 polymerase chain reaction (RT-qPCR) laboratory-developed test (LDT), a cobas

42 SARS-CoV-2 high-throughput system, three direct RT-qPCR kits, and reverse-transcription

43 loop mediated isothermal amplification (RT-LAMP). Viral antigen was detected by a rapid

44 antigen immunochromatographic assay.

45 **Results:** Of the 103 samples, viral RNA was detected in 50.5–81.6% of the specimens by

46 molecular diagnostic tests and an antigen was detected in 11.7% of the specimens by the

47 rapid antigen test. Viral RNA was detected at a significantly higher percentage (65.6–93.4%)

48 in specimens collected within 9 d of symptom onset compared to that of specimens collected

49 after at least 10 d of symptom onset (22.2–66.7%) and that of asymptomatic patients

50 (40.0–66.7%). Viral RNA was more frequently detected in saliva from males than females.

51     **Conclusions:** Self-collected saliva is an alternative specimen diagnosing COVID-19. LDT  
52     RT-qPCR, cobas SARS-CoV-2 high-throughput system, direct RT-qPCR except for one  
53     commercial kit, and RT-LAMP showed sufficient sensitivity in clinical use to be selectively  
54     used according to clinical settings and facilities. The rapid antigen test alone is not  
55     recommended for initial COVID-19 diagnosis because of its low sensitivity.  
56

## 57 **Introduction**

58           Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory  
59   syndrome coronavirus 2 (SARS-CoV-2), was first reported in 2019, in Wuhan, China, and the  
60   World Health Organization subsequently declared it a pandemic [1, 2]. The large number of  
61   patients with COVID-19 during outbreaks is overwhelming the capacity of national health  
62   care systems; therefore, the quick and accurate identification of patients requiring supportive  
63   therapies and isolation is important for the management of COVID-19.

64           The quantitative reverse-transcription polymerase chain reaction (RT-qPCR) assay for  
65   SARS-CoV-2 using upper and lower respiratory tract specimens (nasopharyngeal swab,  
66   throat swab, and sputum) is the gold standard for diagnosing COVID-19 [3]. Laboratory  
67   developed tests (LDT) including RT-qPCR, a high-throughput RT-qPCR system (fully  
68   automated from RNA extraction to reporting of results without the need for highly skilled  
69   laboratory technicians), and direct rapid RNA extraction-free RT-qPCR kits (using a modified  
70   RT-qPCR master mix), have been widely used worldwide [4]. Other molecular diagnostic  
71   methods such as reverse-transcription loop mediated isothermal amplification (RT-LAMP)  
72   have also been reported as useful for diagnosing COVID-19 in point-of care testing [5, 6].  
73   Recently, a SARS-CoV-2 rapid antigen test (RAT) (ESPLINE® SARS-CoV-2; Fuji Rebio  
74   Inc., Tokyo, Japan), which combines immunochromatography with an enzyme immunoassay  
75   to detect the viral nucleocapsid protein, has been approved by the Japanese government [7].

76 The RAT is beginning to be used for diagnosing COVID-19 in clinical settings because it  
77 does not require special equipment, it does not have a time-consuming protocol, and highly  
78 skilled laboratory technicians are not essential. Although these diagnostic tests are useful in  
79 the identification of patients with COVID-19, the process of collecting upper and lower  
80 respiratory tract specimens increases the risk of exposure to viral droplets and there is a  
81 patient burden [8]. Therefore, an alternative specimen, which can be self-collected, to  
82 diagnose COVID-19 is desirable for the clinical management of COVID-19 during this  
83 pandemic era [8].

84 The sensitivity of RT-qPCR on upper respiratory specimens has been reported lower  
85 (32% for pharyngeal swab, and 63% for nasopharyngeal swabs) than lower respiratory  
86 specimens (72% for sputum, and 93% for bronchoalveolar lavage fluid) [9]. Recently, several  
87 reports highlighted the clinical usefulness of RT-qPCR analysis of saliva specimens [10-15].  
88 Saliva specimens can be easily collected by the patients themselves by spitting into a  
89 collection tube; thus, using saliva specimens can reduce the burden on a patient, reduce the  
90 risk of exposure to viral droplets for medical workers, and reduce the time and cost of the  
91 testing procedure [16]. However, the clinical usefulness of saliva specimens for diagnosing  
92 COVID-19 remains controversial because the diagnostic sensitivity also vary widely between  
93 69.2 and 100% for COVID-19, and it has yet to be thoroughly evaluated due to the small  
94 sample size and lack of detailed clinical information [10-15, 17].

95 Here, we describe the clinical performance of various molecular diagnostic methods  
96 including LDT RT-qPCR, cobas SARS-CoV-2 high-throughput system, 3 direct RT-qPCR  
97 kits and RT-LAMP, and a commercial SARS-CoV-2 RAT on self-collected saliva specimens  
98 in diagnosing COVID-19.

99

## 100 **Materials and methods**

### 101 *Patients and sample collection*

102 Patients with COVID-19 were enrolled in this study after being referred to the  
103 Self-Defense Forces Central Hospital in Japan for isolation and treatment under the Infectious  
104 Disease Control Law in effect from Feb 11 to May 13, 2020. All patients were examined for  
105 the SARS-CoV-2 virus by RT-qPCR using pharyngeal and nasopharyngeal swabs collected at  
106 public health institutes or hospitals in accordance with the nationally recommended method  
107 in Japan [18]. On the day of admission, saliva specimens (~500  $\mu$ L) were self-collected by all  
108 patients by spitting into a sterile tube. All samples were stored at -80 °C until sample  
109 preparation. All sample preparation and sample analysis were conducted by SRL, Inc. (Tokyo,  
110 Japan).

### 111 *Sample preparation*

112 Saliva specimens were diluted with phosphate-buffered saline at a volume 1–5 times in  
113 accordance with the consistency and mixed with a vortex mixer. The suspension was

114 centrifuged at  $20,000 \times g$  for 30 min at 4 °C and the supernatant was used in the following  
115 molecular diagnostic and RAT.

116 ***Detection of viral RNA by LDT RT-qPCR using the standard protocol***

117 LDT RT-qPCR was performed according to the National Institution Infections Diseases  
118 (NIID) protocol which is nationally recommended for SARS-CoV-2 detection in Japan [18].  
119 Viral RNA was extracted from 140  $\mu$ L saliva specimens using a QIASymphony™ RNA Kit  
120 (QIAGEN, Hilden, Germany) following the manufacturer's instructions. RT-qPCR  
121 amplification of the SARS-CoV-2 nucleocapsid (N) protein gene was performed using the  
122 QuantiTect®Probe RT-PCR Kit (QIAGEN) with the following sets of primers and probe. N-1  
123 set: forward primer 5' –CAC ATT GGC ACC CGC AAT C - 3', reverse primer 5' – GAG  
124 GAA CGA GAA GAG GCT TG - 3', probe 5' - FAM – ACT TCC TCA AGG AAC AAC ATT  
125 GCC A - TAMRA- 3' [19]. N-2 set: forward primer 5' - AAA TTT TGG GGA CCA GGA AC  
126 - 3', reverse primer 5' - TGG CAG CTG TGT AGG TCA AC - 3', probe 5' - FAM - ATG TCG  
127 CGC ATT GGC ATG GA - TAMRA- 3' [18]. A positive result with either or both of the  
128 primer and probe sets indicated the presence of viral RNA.

129 ***Detection of viral RNA by direct RT-qPCR method without RNA extraction***

130 Direct RT-qPCR methods without RNA extraction were performed using three  
131 commercial kits: Method A, SARS-CoV-2 Direct Detection RT-qPCR Kit (Takara Bio Inc.  
132 Kusatsu, Japan); Method B, Ampdirect™ 2019 Novel Coronavirus Detection Kit (Shimadzu

133 Corporation, Kyoto, Japan); and Method C, SARS-CoV-2 Detection Kit (Toyobo, Osaka,  
134 Japan) according to the manufacturers' instructions. The kits B and C were used with the  
135 same primer sets as used in the LDT RT-qPCR method. The kit A was used with the primer  
136 sets recommended by Centers for Disease Control and Prevention (CDC) [20]. Processed  
137 saliva specimens were directly added to the RT-qPCR master mix and then to thermal cycling,  
138 directly. Methods A and C are quantitative, whereas method B is qualitative.

#### 139 ***Detection of viral RNA by automated RT-qPCR device***

140 The cobas SARS-CoV-2 test (Roche, Basel, Switzerland) [7, 21] was performed on the  
141 RT-qPCR automated cobas 8800 system (Roche) [4]. Specimens (600 µL) were loaded onto  
142 the cobas 8800 with cobas SARS-CoV-2 master mix containing an internal RNA control,  
143 primers, and probes targeting the specific SARS-CoV-2 open reading frame (ORF) 1 gene  
144 (target 1) and envelope (E) gene (target 2). A cobas 8800 positive result for the presence of  
145 SARS-CoV-2 RNA was defined as “detected” if targets 1 and 2 were detected or  
146 “presumptive positive” if target 1 was not detected but target 2 was detected.

#### 147 ***Detection of viral RNA by RT-LAMP***

148 RT-LAMP detection of SARS-CoV-2 was performed using a Loopamp®  
149 2019-SARS-CoV-2 Detection Reagent Kit (Eiken Chemical, Tokyo, Japan) according to the  
150 manufacturer's instructions. The reaction was conducted at 62.5 °C for 35 min with the  
151 turbidity measuring real-time device LoopampEXIA® (Eiken Chemical).



152 ***Detection of SARS-CoV-2 viral antigen by rapid antigen test***

153           RAT was performed using ESPLINE® SARS-CoV-2 (Fuji Rebio Inc) according to the  
154 manufacturer's instructions. In brief, the sample for analysis was obtained by dipping a swab  
155 which was provided by a RAT kit into the saliva specimen and then into the sample  
156 preparation mixture provided by the kit. The mixture (200 µL) was added to the sample port  
157 of the antigen assay. Subsequently, 2 drops of buffer were added and the results were  
158 interpreted after a 30 min incubation.

159 ***Definitions***

160           The saliva sample collection day was defined as day 1. Symptomatic cases were  
161 subdivided into two groups [22]. Severe symptomatic cases were defined as patients showing  
162 clinical symptoms of pneumonia (dyspnea, tachypnea, saturation of percutaneous oxygen  
163 [SpO<sub>2</sub>] < 93%, and the need for oxygen therapy). Other symptomatic cases were classified as  
164 mild cases.

165 ***Ethical statement***

166           Written informed consent was obtained from each enrolled patient at the Self-Defense  
167 Forces Central Hospital. This study was reviewed and approved by the Self-Defense Forces  
168 Central Hospital (approval number 02-024) and International University of Health and  
169 Welfare (20-Im-002-2).

170 ***Statistical analysis***

171 Continuous variables with a normal distribution were expressed as mean ( $\pm$  SD) and  
172 with a non-normal distribution as median (IQR), and compared using the Student's t-test and  
173 Wilcoxon rank-sum test for parametric and nonparametric data, respectively. Categorical  
174 variables were expressed as number (%) and compared by  $\chi^2$  test or Fisher's exact test. The  
175 Kruskal-Wallis test was used for nonparametric analysis with over three independent samples.  
176 Linear regression analysis was used to assess the relationship between each molecular  
177 diagnostic method. A two-sided  $p$  value  $< 0.05$  was considered statistically significant. All  
178 statistical analyses were calculated using R (v3.4.0; R Foundation for Statistical Computing,  
179 Vienna, Austria [<http://www.R-project.org/>]).

180

## 181 **Results**

### 182 *Sensitivity of molecular diagnostic tests and antigen test*

183 In this study, 7 diagnostic tests for COVID-19 were compared across 103 saliva  
184 specimens self-collected by 103 patients (Table 1). Singleton test was conducted for each  
185 method. Among the molecular diagnostic tests, LDT RT-qPCR showed the highest sensitivity  
186 on analyzing the 103 saliva samples. The direct RT-qPCR Method B exhibited higher  
187 sensitivity than either Method A or C. Only 12 patients tested positive using the RAT.

188 The Ct values for the N-1 and N-2 primer sets for the direct RT-qPCR Method C ( $35.5$   
189  $\pm 2.2$  and  $34.8 \pm 2.4$ , respectively) were significantly ( $p < 0.001$ ) greater than those for LDT

190 RT-qPCR ( $32.8 \pm 4.1$  and  $30.1 \pm 4.4$ , respectively) (Figure 1). The mean detection time of  
191 RT-LAMP was 19.1 min (SD = 4.0) (Figure 1). A significant correlation was observed  
192 between RT-LAMP detection time and the Ct value of target 2 in the cobas SARS-CoV-2 test  
193 ( $p < 0.001$ ) (Figure 2A). All patients with a positive SARS-CoV-2 RAT also tested positive  
194 for the six molecular diagnostic tests. The Ct value of target 2 in the cobas SARS-CoV-2 test  
195 was significantly lower in saliva samples that tested positive by RAT compared to that of  
196 samples that tested negative ( $25.4 \pm 1.8$  vs.  $30.8 \pm 2.7$ , respectively;  $p < 0.001$ ; Figure 2B).

#### 197 ***Effect of collection time on test sensitivity***

198 On the day of admission, 15 patients (14.6%) who did not display any symptoms were  
199 classified as asymptomatic, whereas 88 patients (85.4%) were classified as COVID-19  
200 symptomatic. Of the 88 symptomatic patients, saliva specimens were collected by 61 patients  
201 (69.3%) within 9 d from symptom onset (early phase of onset) and by 27 patients (30.7%)  
202 after 10 d from symptom onset (late phase of onset; Table 1). Samples from early phase, late  
203 phase, and asymptomatic patients tested positive by molecular diagnostic tests 65.6–93.4%,  
204 22.3–66.7%, and 40.0–66.7%, respectively. The detection of saliva viral RNA was  
205 significantly higher in symptomatic patients who collected their saliva within 9 d from  
206 symptom onset than in saliva samples collected after 10 d from symptom onset and in saliva  
207 from asymptomatic patients ( $p < 0.01$ ). There were no significant differences in prevalence of  
208 positive results by RAT among the three groups.

209 ***Effect of clinical background on the prevalence of viral RNA in saliva***

210 The baseline clinical characteristics of the 103 patients enrolled in this study are  
211 presented in Table 2. Briefly, patient age ranged from 18 to 87 years (median, 46 years; IQR,  
212 38–63 years), and 66 (64.1%) patients were male. The time from symptom onset to sample  
213 collection was 1–14 d (median, 7 d; IQR, 6–10 d). The time from the initial RT-qPCR  
214 positive test to sample collection was 1–8 d (median, 4 d; IQR, 3–5 d). Of the 88  
215 symptomatic patients, 72 (81.8%) and 16 (18.2%) were classified as mild and severe  
216 COVID-19, respectively.

217 The effect of clinical background against the prevalence of viral RNA in saliva was  
218 analyzed using the results of LDT RT-qPCR, which had the highest sensitivity of all of the  
219 methods in this study. Among 103 patients, a significant male sex bias was noted in samples  
220 that tested positive for the virus compared to that of samples which tested negative (69.0% vs.  
221 42.1%, respectively;  $p = 0.035$ ) (Table 2). There were no significant differences in  
222 distribution by age or disease activity between patients detected or undetected with viral RNA  
223 ( $p > 0.05$ ).

224 A summary of clinical symptoms and disease severity is shown for 88 symptomatic  
225 patients in Table 3. The disease symptom cough was observed in 41 of 74 patients (55.4%)  
226 with viral RNA in their saliva compared to 4 of 14 patients (28.6%) who did not test positive

227 for viral RNA ( $p = 0.084$ ). All severe patients (16/16, 100%) tested positive for viral RNA in  
228 their saliva, while 58 of 72 (78.4%) mild patients tested positive ( $p = 0.064$ ).

229

## 230 **Discussion**

231 Here, we present evidence for the clinical usefulness of saliva specimens in diagnosing  
232 COVID-19. Previous studies reported that the sensitivity of RT-qPCR-analyzed saliva  
233 specimens initially collected from hospitalized patients was 69.2–100% for COVID-19  
234 [10-15, 17]. The contradiction in sensitivity probably reflects differences in the clinical  
235 background and timing of sampling in each study. Becker et al, reported the lowest sensitivity  
236 (69.2%) using the clinical samples which were collected in late phase of onset [17]. On the  
237 other hands, Azzi et al, reported the highest sensitivity on saliva (100%) among hospitalized  
238 patients with severe and very severe disease [11]. In our study, the detection of viral RNA in  
239 saliva was significantly higher in samples collected in the early phase of symptom onset  
240 (within 9 d) compared to that in samples collected in the late phase of symptom onset (over  
241 10 d), and in male patients versus female patients. Since the viral load of SARS-CoV-2 in  
242 saliva has been shown to decline from symptom onset [12], saliva specimens should be  
243 collected during the early phase of symptom onset to increase sensitivity.

244 SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) on host cells found in  
245 the salivary gland and tongue tissues as well as nasal mucosa, nasopharynx, and lung tissue

246 [23, 24] as a cell receptor to invade human cells [25]. Chen et al. collected saliva directly  
247 from the opening of the salivary gland and showed that SARS-CoV-2 can infect salivary  
248 glands [26]. The whole saliva flow rate is known to be higher in males than in females since  
249 it is associated with the size of the salivary gland [27]. The difference in saliva flow rate may  
250 affect the viral load in saliva and be associated with the difference in diagnostic sensitivity  
251 between males and females. We did not observe significant differences in disease severity or  
252 clinical symptoms between patients detected with or without saliva viral RNA; however, the  
253 prevalence of severe disease and the symptom of cough were frequently observed in patients  
254 detected with viral RNA in their saliva. Regarding disease activity, the presence of viral RNA  
255 was detected in more than 50% of the asymptomatic patients. These findings support  
256 previous studies reporting the presence of viral RNA in saliva of both symptomatic and  
257 asymptomatic patients [14]. Therefore, our findings revealed that saliva, collected in the early  
258 phase of symptom onset, is a reliable and practical source for the screening and diagnosing of  
259 COVID-19.

260         The clinical performance of direct RT-qPCR kits and RT-LAMP, and any correlation  
261 with RT-qPCR results were not well evaluated because of the small number of clinical  
262 specimens collected from patients in previous studies [5, 6, 28]. The sensitivity of RT-LAMP  
263 for SARS-CoV-2 using upper and lower respiratory tract specimens has been reported as  
264 equivalent to RT-qPCR [5, 6, 28]. However, our results indicate that the sensitivity of

265 RT-LAMP is inferior to LDT RT-qPCR and cobas SARS-CoV-2 test for COVID-19 in saliva  
266 specimens. Direct RT-qPCR kits without an RNA extraction process can reduce the time, cost,  
267 and human resources needed to conduct the assay. However, we showed that there is a large  
268 difference in sensitivity among the direct RT-qPCR kits. It is necessary to pay attention to the  
269 false-negative results of RT-LAMP and direct RT-qPCR kits, especially when testing saliva  
270 samples. In clinical settings with limited medical and human resources, using RT-LAMP and  
271 direct RT-qPCR kits are options for screening and diagnosing COVID-19 because of their  
272 simplicity.

273         In comparison with molecular diagnostic tests, the SARS-CoV-2 RAT of saliva  
274 specimens showed low sensitivity. The sensitivity of RAT is still unclear, not only when using  
275 saliva samples but also when using nasopharyngeal swab specimens [7]. The experiment to  
276 compare the sensitivity of RT-qPCR and RAT prior to the approval as in vitro diagnostic test  
277 by Japanese government showed that sensitivity of RAT was 66.7% (16/24 patients) for  
278 nasopharyngeal swabs; furthermore, low sensitivity specimens contained a low viral copy  
279 number (50% sensitivity [6/12 patients] for specimens containing < 100 copies/test) [7]. Our  
280 findings also suggest that the RAT requires a high viral copy number to get positive result.  
281 This kit was not originally compatible with saliva specimens and the freeze-thaw process  
282 may have affected sensitivity. Improvements in sample preparation may increase its  
283 sensitivity.

284 Our study had several limitations. First, the saliva specimens were collected from  
285 patients 3 d (median) after receiving their first positive RT-qPCR result from analysis of  
286 upper respiratory specimens. Directly comparing the sensitivity between saliva and other  
287 upper or lower respiratory specimens is difficult in our study design because the viral load in  
288 the clinical specimens vary with time [13]. Second, although the high specificity of RT-qPCR  
289 for SARS-CoV-2 has been confirmed [6, 18, 28-31], the specificities should be analyzed by  
290 also using saliva from non-COVID-19 patients. Further studies are warranted to determine  
291 the usefulness of saliva specimens for screening and diagnosing COVID-19.

292

## 293 **Conclusions**

294 Self-collected saliva in the early phase of symptom onset is an alternative specimen  
295 diagnosing COVID-19. LDT RT-qPCR, cobas SARS-CoV2 high-throughput system, direct  
296 RT-qPCR kits except for one commercial kit, and RT-LAMP showed equivalent and sufficient  
297 sensitivity in clinical use and can be selectively used according to the clinical setting and  
298 facilities. The rapid SARS-CoV-2 antigen test alone is not recommended for use at this time  
299 due to low sensitivity.

300

## 301 **Conflict of interest**

302 The authors declare that they have no conflicts of interests.



303

## 304 **Funding**

305           This work was supported by the Health, Labour and Welfare Policy Research Grants,  
306 Research on Emerging and Re-emerging Infectious Diseases and Immunization [grant  
307 number 20HA2002].

308

## 309 **Acknowledgments**

310           We thank clinical laboratory technicians at the Self-Defense Forces Central Hospital  
311 for sample collecting, and everyone involved in the COVID-19 Task Force at the  
312 Self-Defense Forces Central Hospital, and members who were assembled from other  
313 institutes of the Japan Self-Defense Forces.

314

## 315 **Authors' contributions**

316           YK and KI, study conception and design; MI and ST, collecting data and performing  
317 data analysis; MI, KI, KM, KT and YK manuscript drafting and editing; NM, TM, MH, KK,  
318 YI and MI, manuscript revision; SM, TI and KT, study supervision. All authors have read and  
319 approved the final manuscript.

## 320 **References**

- 321 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel  
322 coronavirus in Wuhan, China. *Lancet* 2020; 395(10223): 497-506.
- 323 2. WHO. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. [Latest  
324 accessed 30/May/2020]
- 325 3. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2.  
326 *JAMA* 2020. DOI:10.1001/jama.2020.8259
- 327 4. Cobb B, Simon CO, Stramer SL, et al. The cobas® 6800/8800 System: a new era of  
328 automation in molecular diagnostics. *Expert Rev Mol Diagn* 2017; 17(2): 167-80.
- 329 5. Yu L, Wu S, Hao X, et al. Rapid detection of COVID-19 coronavirus using a reverse  
330 transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. *Clin*  
331 *Chem* 2020. DOI: <https://doi.org/10.1093/clinchem/hvaa102>
- 332 6. Kitagawa Y, Orihara Y, Kawamura R, et al. Evaluation of rapid diagnosis of novel  
333 coronavirus disease (COVID-19) using loop-mediated isothermal amplification. *J Clin Virol*  
334 2020. DOI: <https://doi.org/10.1016/j.jcv.2020.104446>
- 335 7. Japanese Ministry of Health, Labour and Welfare. Approval of In Vitro  
336 Diagnostics for the novel coronavirus infection/  
337 <https://www.mhlw.go.jp/content/11124500/000632304.pdf>. [Latest accessed 30/May/2020]

- 338 8. Wehrhahn MC, Robson J, Brown S, et al. Self-collection: An appropriate alternative  
339 during the SARS-CoV-2 pandemic. *J Clin Virol* 2020; 128: 104417. DOI:  
340 <https://doi.org/10.1016/j.jcv.2020.104417>
- 341 9. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of  
342 Clinical Specimens. *JAMA* 2020; 323(18): 1843-4.
- 343 10. Pasomsub E, Watcharananan SP, Boonyawat K, et al. Saliva sample as a  
344 non-invasive specimen for the diagnosis of coronavirus disease-2019 (COVID-19): a  
345 cross-sectional study. *Clin Microbiol Infect* 2020.  
346 DOI:<https://doi.org/10.1016/j.cmi.2020.05.001>
- 347 11. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect  
348 SARS-CoV-2. *J Infect* 2020. DOI:<https://doi.org/10.1016/j.jinf.2020.04.005>
- 349 12. To KK-W, Tsang OT-Y, Chik-Yan Yip C, et al. Consistent detection of 2019 novel  
350 coronavirus in saliva. *Clin Infect Dis* 2020. DOI: <https://doi.org/10.1093/cid/ciaa149>
- 351 13. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior  
352 oropharyngeal saliva samples and serum antibody responses during infection by  
353 SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 2020; 20(5): 565-74.
- 354 14. Kojima N, Turner F, Slepnev V, et al. Self-Collected Oral Fluid and Nasal Swabs  
355 Demonstrate Comparable Sensitivity to Clinician Collected Nasopharyngeal Swabs for  
356 Covid-19 Detection. *medRxiv* 2020: 2020.04.11.20062372.

- 357 15. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for  
358 SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. medRxiv 2020:  
359 2020.04.16.20067835.
- 360 16. To KKW, Yip CCY, Lai CYW, et al. Saliva as a diagnostic specimen for testing  
361 respiratory virus by a point-of-care molecular assay: a diagnostic validity study. Clin  
362 Microbiol Infect 2019; 25(3): 372-8.
- 363 17. Becker D, Sandoval E, Amin A, et al. Saliva is less sensitive than nasopharyngeal  
364 swabs for COVID-19 detection in the community setting. medRxiv 2020:  
365 2020.05.11.20092338.
- 366 18. Shirato K, Nao N, Katano H, et al. Development of Genetic Diagnostic Methods for  
367 Novel Coronavirus 2019 (nCoV-2019) in Japan. Jpn J Infect Dis 2020. DOI:  
368 10.7883/yoken.JJID.2020.061
- 369 19. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus  
370 (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25(3): 2000045. DOI: doi:  
371 10.2807/1560-7917.ES.2020.25.3.2000045
- 372 20. Centers for Disease Control and Prevention. Research Use Only 2019-Novel  
373 Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes.  
374 <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>. [Latest  
375 accessed 30/May/2020]

- 376 21. U.S. Food and Drug Administration. cobas@SARS-CoV-2.  
377 <https://www.fda.gov/media/136049/download>. [Latest accessed 30/May/2020]
- 378 22. Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage  
379 strategies for 2019 novel coronavirus disease in fever clinics. *Lancet Respir Med* 2020; 8(3):  
380 e11-e2.
- 381 23. Song J, Li Y, Huang X, et al. Systematic Analysis of ACE2 and TMPRSS2  
382 Expression in Salivary Glands Reveals Underlying Transmission Mechanism Caused by  
383 SARS-CoV-2. *J Med Virol* 2020. DOI: <https://doi.org/10.1002/jmv.26045>
- 384 24. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue  
385 distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in  
386 understanding SARS pathogenesis. *J Pathol* 2004; 203(2): 631-7.
- 387 25. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends  
388 on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;  
389 181(2): 271-80.e8.
- 390 26. Chai X, Hu L, Zhang Y, et al. Specific ACE2 Expression in Cholangiocytes May  
391 Cause Liver Damage After 2019-nCoV Infection. *bioRxiv* 2020: 2020.02.03.931766.
- 392 27. Inoue H, Ono K, Masuda W, et al. Gender difference in unstimulated whole saliva  
393 flow rate and salivary gland sizes. *Arch Oral Biol* 2006; 51(12): 1055-60.

- 394 28. Lieberman JA, Pepper G, Naccache SN, Huang M-L, Jerome KR, Greninger AL.  
395 Comparison of Commercially Available and Laboratory Developed Assays for in vitro  
396 Detection of SARS-CoV-2 in Clinical Laboratories. J Clin Microbiol 2020. DOI:  
397 10.1128/JCM.00821-20
- 398 29. Pfefferle S, Reucher S, Nörz D, Lütgehetmann M. Evaluation of a quantitative  
399 RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high  
400 throughput system. Euro Surveill 2020; 25(9): 2000152.
- 401 30. Okamaoto K, Shirato K, Nao N, et al. An assessment of real-time RT-PCR kits for  
402 SARS-CoV-2 detection. Jpn J Infect Dis 2020. DOI:  
403 <https://doi.org/10.7883/yoken.JJID.2020.108>
- 404 31. Yan C, Cui J, Huang L, et al. Rapid and visual detection of 2019 novel coronavirus  
405 (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay. Clin  
406 Microbiol Infect 2020; 26(6): 773-9.

407

408

#### 409 **Figure Legends**

410 **Figure 1. Ct value and detection time for each molecular diagnostic test of saliva**

411 **specimens.** Cycle threshold (Ct) value for each RT-qPCR primer set and detection time by

412 reverse-transcription loop mediated isothermal amplification (RT-LAMP). Horizontal lines  
413 indicate the mean Ct value or detection time.  $p$  value was calculated using the Student's t-test.

414

415 **Figure 2. Relation of RT-qPCR, RT-LAMP, and rapid antigen test of saliva specimens.**

416 (A) Relation between detection time of reverse-transcription loop mediated isothermal  
417 amplification (RT-LAMP) and Ct value of target 2 (SARS-CoV-2 envelope gene) in cobas  
418 SARS-CoV-2 test. The blue slope line represents the fitted regression curve. The gray shadow  
419 indicates a 95% confidence interval around the regression curve. (B) Distribution of Ct value  
420 of target 2 in cobas SARS-CoV-2 test of saliva with positive and negative results. Horizontal  
421 lines indicate the mean Ct value.  $p$  value was calculated using the Student's t-test.

422

423

424 **Table 1. Summary of results of molecular diagnostic tests and rapid antigen test for**  
 425 **COVID-19 on self-collected saliva samples.**

	Total n = 103	Time from onset to collection		Asymptomatic n = 15	p value <sup>a</sup>
		Early phase (≤ 9 days) n = 61	Late phase (9 days <) n = 27		
<b>LDT RT-qPCR<sup>b</sup></b>	84 (81.6) [72.7-88.5]	57 (93.4) [84.1-98.2]	17 (63.0) [42.4-80.6]	10 (66.7) [38.4-88.2]	< 0.001
<b>N-1 set</b>	76 (73.8) [64.2-82.0]	54 (88.5) [77.8-95.2]	14 (51.9) [31.9-71.3]	8 (53.3) [26.6-78.7]	
<b>N-2 set</b>	83 (80.6) [71.6-87.7]	57 (93.4) [84.1-98.2]	16 (59.3) [38.8-77.6]	10 (66.7) [38.4-88.2]	
<b>cobas SARS-CoV2 test</b>	83 (80.6) [71.6-87.7]	56 (91.8) [81.9-97.3]	18 (66.7) [46.0-83.5]	9 (60.0) [32.3-83.7]	< 0.001
<b>Target 1</b>	76 (73.8) [64.2-82.0]	54 (88.5) [77.8-95.2]	14 (51.9) [31.9-71.3]	8 (53.3) [26.6-78.7]	
<b>Target 2</b>	83 (80.6) [64.2-82.0]	56 (91.8) [81.9-97.3]	18 (66.7) [46.0-83.5]	9 (60.0) [32.3-83.7]	
<b>Direct RT-qPCR</b>					



<b>Method A<sup>c</sup></b>	79 (76.7) [67.3-84.5]	53 (86.9) [75.8-94.2]	16 (59.3) [38.8-77.6]	10 (66.7) [38.4-88.2]	0.012
<b>Method B<sup>d</sup></b>	81 (78.6) [69.5-86.1]	55 (90.2) [79.8-96.3]	17 (63.0) [42.4-80.6]	9 (60.0) [32.3-83.7]	0.003
<b>N-1 set</b>	80 (77.7) [68.4-85.3]	54 (88.5) [77.8-95.3]	17 (63.0) [42.4-80.6]	9 (60.0) [32.3-83.7]	
<b>N-2 set</b>	63 (61.2) [51.1-70.6]	48 (78.7) [66.3-88.1]	8 (29.6) [13.8-50.2]	7 (46.7) [21.3-73.4]	
<b>Method C<sup>e</sup></b>	52 (50.5) [40.5-60.5]	40 (65.6) [52.3-77.3]	6 (22.2) [8.6-42.3]	6 (40.0) [16.3-67.7]	< 0.001
<b>N-1 set</b>	15 (14.6) [8.4-22.9]	9 (14.8) [7.0-26.1]	2 (7.4) [1.0-24.3]	4 (26.7) [7.8-55.1]	
<b>N-2 set</b>	51 (49.5) [39.5-59.5]	40 (65.6) [52.3-77.3]	6 (22.2) [8.6-42.3]	5 (33.3) [11.8-61.6]	
<b>RT-LAMP</b>	73 (70.9) [61.1-79.4]	52 (85.2) [73.8-93.0]	12 (44.4) [25.5-64.7]	9 (60.0) [32.3-83.7]	< 0.001
<b>Rapid antigen test</b>	12 (11.7) [6.2-19.5]	8 (13.1) [5.8-24.2]	2 (7.4) [1.0-24.3]	2 (13.3) [1.7-40.5]	0.728

426 Data are presented as n (%) [95% confidence interval], unless otherwise specified.

427 <sup>a</sup>*p* value was calculated using Kruskal-Wallis test.

428 <sup>b</sup>LDT, Laboratory-developed test.

429 <sup>c</sup>Method A, SARS-CoV-2 Direct Detection RT-qPCR Kit (Takara Bio Inc. Kusatsu, Japan).

430 <sup>d</sup>Method B, Ampdirect™ 2019 Novel Coronavirus Detection Kit (Shimadzu Corporation,

431 Kyoto, Japan).

432 <sup>e</sup>Method C, SARS-CoV-2 Detection Kit (Toyobo, Osaka, Japan).

433

434 **Table 2. Effect of clinical background against the presence of viral RNA in saliva of 103**  
 435 **asymptomatic and symptomatic patients**

	Presence of viral RNA in saliva			<i>p</i> value <sup>a</sup>
	Total n = 103	Positive n = 84	Negative n = 19	
<b>Age (years)</b>	48 [36–63]	47 [39-67]	44 [38-55]	0.195
<b>Sex</b>				0.035
<b>Male</b>	66 (64.1)	58 (69.0)	8 (42.1)	-
<b>Female</b>	37 (35.9)	26 (31.0)	11 (57.9)	-
<b>Disease activity</b>				0.146
<b>Asymptomatic</b>	15 (14.6)	10 (11.9)	5 (26.3)	-
<b>Symptomatic</b>	88 (85.4)	74 (88.1)	14 (73.7)	-

436 Data are presented as n (%) or median [interquartile range], unless otherwise specified.

437 <sup>a</sup>*p* value was calculated using Wilcoxon rank-sum test for continuous variable, and  $\chi^2$  test or

438 Fisher’s exact test for categorical variables.

439

440 **Table 3. Effect of clinical background against the presence of viral RNA in saliva of 88**

441 **symptomatic patients**

	Presence of viral RNA in			<i>p</i> value <sup>a</sup>
	Symptomatic patients n = 88	saliva		
		Positive n = 74	Negative n = 14	
<b>Age (years-old)</b>	46 [38-62]	46 [38-60]	44 [37-53]	0.344
<b>Sex (male)</b>				0.011
<b>Male</b>	59 (67.0)	54 (73.0)	5 (35.7)	-
<b>Female</b>	29 (33.0)	20 (27.0)	9 (64.3)	-
<b>Disease severity</b>				0.064
<b>Mild</b>	72 (81.8)	58 (78.4)	14 (100)	-
<b>Severe</b>	16 (18.2)	16 (21.6)	-	-
<b>Clinical symptoms</b>				
<b>Fever</b>	73 (83.0)	62 (83.8)	11 (78.6)	0.700
<b>Cough</b>	45 (51.1)	41 (55.4)	4 (28.6)	0.084
<b>Malaise</b>	30 (34.1)	25 (33.8)	5 (35.7)	1.000
<b>Headache</b>	25 (28.4)	22 (29.7)	3 (21.4)	0.749

<b>Diarrhea</b>	20 (22.7)	15 (20.3)	5 (35.7)	0.294
<b>Sore throat</b>	19 (21.6)	15 (20.3)	4 (28.6)	0.491
<b>Tachypnea</b>	13 (14.8)	13 (17.6)	-	0.117
<b>Dyspnea</b>	8 (9.1)	8 (10.8)	-	0.346
<b>Hypoxemia (SpO<sub>2</sub> &lt; 93 %)</b>	10 (11.4)	10 (13.5)	-	0.353

---

442 Data are presented as n (%) or median [interquartile range], unless otherwise specified.

443 <sup>a</sup>*p* value was calculated using Wilcoxon rank-sum test for continuous variable, and  $\chi^2$  test or

444 Fisher's exact test for categorical variables.

Figure 1




Figure 2

